医学
杜瓦卢马布
银耳霉素
卡铂
化疗
紫杉醇
肿瘤科
内科学
临床终点
新辅助治疗
封锁
癌症
卵巢癌
顺铂
临床试验
免疫疗法
无容量
乳腺癌
易普利姆玛
受体
作者
Alexandra Léary,Thibault De La Motte Rouge,Alain Lortholary,Bernard Asselain,Jérôme Alexandre,Anne Floquet,A.M. Savoye,Laure Chardin,Nicolas Delanoy,Céline Gavoille,Benoît You,Véronique D’Hondt,Julien Grenier,Catherine Genestie,Éric Pujade-Lauraine
标识
DOI:10.1016/j.annonc.2021.08.1170
摘要
We have shown that neoadjuvant carboplatin and paclitaxel (NACP) increased tumor-infiltrating lymphocytes and PDL1 expression in OC pts. Combined PDL1/CTLA4 blockade is active in relapsed OC. INEOV is the 1st trial of neoadjuvant D +/- T with NACP in pts with unresectable OC. Main endpoints are feasibility and safety. 2° endpoints include macroscopically complete resection (CCO) and major pathological response rates after 3 cycles (C3).
科研通智能强力驱动
Strongly Powered by AbleSci AI